A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab

Clinical and Experimental Rheumatology

Volumn 27, Issue 1, 2009, Pages 124-127

  Papagoras, Charalampos E ^a   Argyropoulou, Maria I ^b   Voulgari, Paraskevi V ^a   Vrabie, Ileana ^a   Zikou, Anastasia K ^b   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Anti TNF agents; Brucella spondylitis; Infliximab; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; DOXYCYCLINE; INFLIXIMAB; RIFAMPICIN;

AGED; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BRUCELLA; BRUCELLOSIS; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; LOW BACK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; SERODIAGNOSIS; SIDE EFFECT; SPONDYLITIS; TREATMENT RESPONSE;

AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; BRUCELLOSIS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNITY, INNATE; RIFAMPIN; SPONDYLITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63049088419     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. PAPPAS G, AKRITIDIS N, BOSILKOVSKI M, TSIANOS E: Brucellosis. N Engl J Med 2005; 352: 2325-36.
2. PAPPAS G, SEITARIDIS S, AKRITIDIS N, TSIANOS E: Treatment of brucella spondylitis: Lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004; 24: 502-7.
3. JIMÉNEZ FG, COLMENERO JD, IRIGOYEN MV: Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis. J Infect 2005; 50: 370-1.
4. BARQUERO-CALVO E, CHAVES-OLARTE E, WEISS DS et al.: Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS ONE 2007; 2: e631.
5. CORBEL MJ, BEECHING NJ: Brucellosis in Harrison's Principles of Internal Medicine, vol 1. In KASPER DL, FAUCT AS, LONGO DL, BRAUNWALD E, HAUSER SL, JAMESON JL (Eds) Infectious Diseases. McGraw-Hill 2005: 914-7.
6. REFIK M, MEHMET N, DURMAZ R, ERSOY Y: Cytokine profile and nitric oxide levels in sera from patients with brucellosis. Braz J Med Biol Res 2004; 37: 1659-63.
7. BILLARD E, DORNAND J, GROSS A: Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion. Infect Immun 2007; 75: 4980-9.
8. DORNAND J, GROSS A, LAFONT V, LIAUTARD J, OLIARO, J, LIAUTARD JP: The innate immune response against Brucella in humans. Vet Microbiol 2002; 90: 383-94.
9. ZHAN Y, LIU Z, CHEERS C: Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun 1996; 64: 2782-6.
10. PAPPAS G, PAPADIMITRIOU P, AKRITIDIS N, CHRISTOU L, TSIANOS EV: The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91-9.
11. VOROU R, GKOLFINOPOULOU K, DOUGAS G, MELLOU K, PIERROUTSAKOS IN, PAPADIMITRIOU T: Local brucellosis outbreAk on Thassos, Greece: a preliminary report. Euro Surveill 2008; 13 pii: 18910.
12. MINAS M, MINAS A, GOURGULIANIS K, STOURNARA A: Epidemiological and clinical aspects of human brucellosis in Central Greece. Jpn J Infect Dis 2007; 60: 362-6.
13. MCQUEEN F, LASSERE M, ØSTERGAARD M: Magnetic resonance imaging in psoriatic arthritis: A review of the literature. Arthritis Res Ther 2006; 8: 207.
14. JEVTIC V, KOS-GOLJA M, ROZMAN B, MCCALL I: Marginal erosive discovertebral "Romanus" lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol 2000; 29: 27-33.